--- title: "U.S. stock market midday update: Decoy Therapeutics up 13.04%, influx of funds boosts volatility" type: "News" locale: "en" url: "https://longbridge.com/en/news/292232688.md" description: "Decoy Therapeutics rose 13.04%; Alibaba's Lam Pharmaceutical fell 0.15%, with a transaction volume of USD 1.678 billion; Bridgebio Pharma rose 17.07%, with a transaction volume of USD 1.38 billion; Ionis Pharmaceuticals fell 23.24%, with a transaction volume of USD 1.046 billion; AbbVie fell 1.76%, with a market capitalization of USD 438.6 billion" datetime: "2026-07-09T18:47:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292232688.md) - [en](https://longbridge.com/en/news/292232688.md) - [zh-HK](https://longbridge.com/zh-HK/news/292232688.md) generator: "portal-rs" --- # U.S. stock market midday update: Decoy Therapeutics up 13.04%, influx of funds boosts volatility **U.S. Stock Market Midday Update** Decoy Therapeutics, up 13.04%, with increased trading volume and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks with High Trading Volume in the Industry** Alnylam Pharmaceuticals down 0.15%. Based on recent key news: 1. On July 9, AstraZeneca's drug Wainua, developed in collaboration with Ionis, failed to meet its primary endpoint in late-stage trials, causing Ionis's stock to plummet by 21.8%. This failure is beneficial for Alnylam Pharmaceuticals, as the failure of its market competitor may enhance its market share. Source: MarketWatch 2. On July 9, AstraZeneca's gene-silencing drug failed to meet expected sales targets, and analysts believe this could damage its reputation. This event indirectly benefits Alnylam Pharmaceuticals, as its competitors in the same field face challenges. Source: MarketWatch 3. On July 9, Alnylam Pharmaceuticals' competitors, Alnylam and BridgeBio, saw their stock prices rise by 18% and 15%, respectively, due to increased market demand for their drugs. This indicates strong demand for drugs in this field, which may positively impact Alnylam Pharmaceuticals. Source: MarketWatch The gene-silencing drug market is highly competitive, with strong demand. BridgeBio Pharma up 17.07%. Based on recent key news: 1. On July 9, AstraZeneca's gene-silencing drug trial failed, leading to setbacks for BridgeBio's competitors. The trial did not meet its primary goals of reducing cardiovascular deaths and recurrent heart issues, and analysts believe this damages AstraZeneca's reputation. This news is favorable for BridgeBio, pushing its stock price up by about 15%. 2. On July 8, JP Morgan began coverage of BridgeBio's stock with an "Overweight" rating and a target price of $27. This move has boosted market confidence in BridgeBio, further driving up its stock price. 3. On July 9, Ionis Pharmaceuticals' trial for a neurological disease drug failed, causing its stock to drop significantly. This news is also favorable for BridgeBio, as reduced market competition led to a stock price increase of about 9.9%. The gene therapy field is highly competitive, with significant market volatility. Ionis Pharmaceuticals down 23.24%. Based on recent key news: 1. On July 9, Ionis Pharmaceuticals' drug eplontersen, developed in collaboration with AstraZeneca, failed to meet its primary efficacy endpoint in the Phase 3 CARDIO-TTRansform study for the ATTR-CM indication, leading to a pre-market drop of over 21% 2. On July 10, the clinical trial results from Ionis Pharmaceuticals negatively impacted Wainua's independent benefit assessment. TD Cowen analysts maintained a buy rating but lowered the target price from $108 to $94. 3. On July 9, analysts pointed out that the trial failure could damage AstraZeneca's management credibility. Nevertheless, Jefferies analysts believe this will not hinder AstraZeneca from achieving its goal of $80 billion in annual sales by 2030. The clinical trial failure led to a significant drop in stock prices and intensified industry competition. **Stocks Ranked Among the Top by Market Capitalization in the Industry** AbbVie fell 1.76%, with increased trading volume. Based on recent key news: 1. On July 6, AbbVie announced that its Tepkinly® combination therapy received EU approval for the treatment of relapsed or refractory follicular lymphoma. This approval could have a positive impact on the company's sales in the European market but failed to immediately boost the stock price. 2. On July 7, Morgan Stanley raised AbbVie's target price to $279, expecting its second-quarter revenue to exceed market consensus, although earnings per share were slightly below expectations. This analyst rating adjustment did not significantly change market sentiment. 3. On July 7, AbbVie anticipated that the second quarter would include $291 million in R&D and milestone expenses, impacting earnings per share by $0.17. This financial forecast adjustment could negatively affect investor confidence. The fundamentals of the biopharmaceutical industry will dominate performance in the second half of the year ### Related Stocks - [DCOY.US](https://longbridge.com/en/quote/DCOY.US.md) - [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md) - [BBIO.US](https://longbridge.com/en/quote/BBIO.US.md) - [IONS.US](https://longbridge.com/en/quote/IONS.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) ## Related News & Research - [Vise Technologies Inc. Takes $743,000 Position in Halozyme Therapeutics, Inc. $HALO](https://longbridge.com/en/news/296763264.md) - [Mitsubishi UFJ Asset Management Co. Ltd. Purchases Shares of 32,564 Viking Therapeutics, Inc. $VKTX](https://longbridge.com/en/news/296678166.md) - [Bank of America Corp DE Increases Position in Structure Therapeutics Inc. Sponsored ADR $GPCR](https://longbridge.com/en/news/296749948.md) - [BlackRock Inc. Makes New $1.08 Billion Investment in Corcept Therapeutics Incorporated $CORT](https://longbridge.com/en/news/296675400.md) - [Spruce Street Capital LP Purchases Shares of 2,984,125 Relay Therapeutics, Inc. $RLAY](https://longbridge.com/en/news/296889683.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**